<DOC>
	<DOCNO>NCT00327145</DOCNO>
	<brief_summary>This study design provide additional efficacy safety data treatment strategy base combination valsartan amlodipine hypertensive patient previously treat monotherapy remain uncontrolled . A naturalistic approach take compare two different dos , i.e . 160mg valsartan amlodipine 5mg 10mg possible addition HCTZ</brief_summary>
	<brief_title>A Study Evaluate Combination Valsartan Amlodipine Hypertensive Patients Not Controlled Monotherapy</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>Inclusion criterion Male female patient ≥18 year age Nondiabetic patient must MSSBP ≥140 mmHg and/or MSDBP ≥90 mmHg Visits 1 2 . Diabetic patient must MSSBP ≥130 mmHg and/or MSDBP ≥80 mmHg Visits 1 2 Patients treated monotherapy dose consider adequate investigator minimum two month prior Visit 1 Exclusion criterion Known suspect contraindication , include history allergy ARBs , CCB , thiazides drug similar chemical structure . MSSBP ≥180 mmHg and/or MSDBP ≥110 mmHg ( MSSBP ≥160 mmHg and/or MSDBP ≥100 mmHg diabetic patient ) time Visit 1 Visit 2 . Evidence secondary form hypertension , include coarctation aorta , primary hyperaldosteronism , renal artery stenosis , pheochromocytoma . Known KeithWagener grade III IV hypertensive retinopathy . Other exclusion criterion apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>HCTZ</keyword>
	<keyword>hypertension</keyword>
	<keyword>valsartan</keyword>
	<keyword>amlodipine</keyword>
</DOC>